2'-O-MOE Phosphoramidites

What Are 2'-O-MOE Phosphoramidites?
2'-O-Methoxyethyl (2'-O-MOE or 2'-MOE) phosphoramidites are nucleotide monomers in which the 2'-hydroxyl of the ribose sugar is replaced by a methoxyethyl (—O—CH₂—CH₂—O—CH₃) side chain via an ether linkage. They represent the most emblematic sugar modification of second-generation antisense oligonucleotide (ASO) technology. Replacing the natural 2'-OH of RNA with this hydrophilic methoxyethyl group, the MOE modification simultaneously imparts three core properties to oligonucleotides—exceptional nuclease resistance, high target binding affinity, and low cytotoxicity—while preserving Watson–Crick base-pairing fidelity, making it the most widely used chemical modification among approved ASO drugs to date.

The structure–activity basis of MOE modification lies in its unique stereoelectronic configuration: the methoxyethyl side chain stabilizes the ribose ring in the C3'-endo (A-form helix conformation), effectively pre-organizing the oligonucleotide into an A-type duplex geometry. When a 2'-MOE-modified ASO hybridizes with complementary RNA, this conformational preference significantly elevates duplex thermal stability (Tm increases of approximately 2–4 °C per modification site). Furthermore, the MOE side chain creates a “hydration shell” around the sugar ring, shielding the backbone and substantially enhancing resistance to nuclease degradation, resulting in serum half-lives far exceeding those of natural RNA. Importantly, MOE modification has been shown to significantly reduce non-specific protein binding and immunostimulatory potential, demonstrating good in vivo safety profiles^[1-5].

A standard 2'-O-MOE phosphoramidite monomer comprises the following structural features:

1. Sugar Backbone – 2'-O-methoxyethylribose, where the natural 2'-hydroxyl of ribose is replaced by a methoxyethyl (—O—CH₂—CH₂—O—CH₃) group. This glycol ether side chain is highly hydrophilic, chemically stable, and unaffected by standard synthesis and deprotection conditions.
2. Nucleobase & Protecting Groups:
   
   • Natural bases include A, G, C, U (RNA format) or T (DNA format), with modified bases such as 5-methyl-dC also available.
   • Exocyclic amines on the bases are acyl-protected, with common combinations including benzoyl (Bz) for A (Cat. No. PR1-004) or phenoxyacetyl (Pac) mild-deprotection version (Cat. No. PR1-110); dmf fast-deprotection for G (Cat. No. PR2-019) or Pac mild-deprotection version (Cat. No. PR2-108); and acetyl (Ac) for C or benzoyl (Bz) for C (Cat. No. PR3-130), with Bz providing stronger protection.
   • 5-Methyl-dC (Ac) version (Cat. No. PR3-017) is available for epigenetic research and related applications.
   • For mild deprotection requirements, Hongene offers Pac-protected versions (A and G), compatible with base-sensitive fluorescent dyes and functional group labels.
3. 5'-O-DMT and 3'-CE Phosphoramidite Groups – The 5'-DMT reversibly blocks the 5'-hydroxyl to ensure single-monomer addition per cycle. The 3'-cyanoethyl (CE) phosphoramidite group, upon activation (e.g., by tetrazole), couples to the free 5'-OH of the growing chain, and the resulting phosphite triester is oxidized to a stable phosphate diester with iodine/water.
4. Phosphorothioate Backbone Variants – Hongene also offers 3'-phosphorothioate (PS) versions of MOE monomers (where a non-bridging oxygen atom on the phosphorus is replaced by sulfur), enabling systematic introduction of PS backbone modifications to further enhance nuclease resistance. These monomers are suitable for in vivo applications requiring exceptionally high biostability. Representative products include MOE-A-PS (Cat. No. PR1-036) and 5'-DMT-2'-O-MOE-5-Me-C(Bz)-3'-PS-Phosphoramidite. In automated solid-phase synthesis, 2'-O-MOE phosphoramidites follow the standard four-step cycle with a recommended coupling time of 6 minutes, compatible with conventional DNA/RNA synthesis parameters. Deprotection can be achieved with concentrated ammonia at 55 °C for 8 hours or AMA (ammonia/methylamine, 1:1 v/v) at 65 °C for 10 minutes. Because the MOE modification is stable under deprotection conditions and the resulting products are nuclease-resistant, deprotection, isolation and handling procedures are similar to those for oligodeoxynucleotides, requiring no special RNase-free precautions.